Compare Halliburton Company (HAL) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halliburton Company vs Nuvalent Inc — how do they compare? Halliburton Company trades at $33.38 (market cap $29.33B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Halliburton Company is far larger — about 3× Nuvalent Inc's market cap, and Halliburton Company pays a 1.94% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.
| HAL | NUVL | |
|---|---|---|
Market Cap | $29.33B | $9.81B |
Sector | Energy | Technology |
52-Week High | $42.98 | $123.96 |
52-Week Low | $20.50 | $72.16 |
Enterprise Value | $35.41B | $8.52B |
Dividend Yield | 1.94% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Halliburton (HAL) trades at $33.19, down 5.76% on the day, amid a neutral technical signal and bearish moving averages. The company reported Q2 2026 EPS of $0.55, beating estimates, with revenue up 6% sequentially to $5.7 billion, driven by international growth. Despite strong earnings, the stock declined due to management's caution on near-term market softness. Key financials show a P/E of 19.4 and ROE of 14.56%, with net income of $1.28 billion in 2025.
Outlook remains mixed: analyst consensus is bullish with a $44.78 price target, but risks include oilfield services volatility and Middle East disruptions. The recent contract wins in Saudi Arabia and Iraq support growth, yet investor sentiment is cautious post-earnings. The stock offers value with solid cash flow, but macroeconomic and sector-specific headwinds pose challenges for near-term performance.
Nuvalent (NUVL) trades at $123.96, showing no change recently, with technical indicators presenting a mixed signal—moving averages are bullish while oscillators are bearish. The company reported a net loss of $425.38 million for 2025, with negative profitability metrics like ROE of -41.19%. Recent news highlights GSK's proposed acquisition of Nuvalent for $124 per share, totaling $10.6 billion, which is under investigation by multiple law firms for fairness concerns.
The investment outlook is heavily influenced by the pending acquisition, offering a near-term exit at $124 per share. However, risks include ongoing financial losses, negative cash flow from operations, and legal scrutiny over the deal's adequacy. Analyst sentiment is mixed with 42% buy ratings, but the acquisition provides a clear valuation anchor amid fundamental challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
